Verrica Pharmaceuticals (FRA:1NE) Total Liabilities : €59.62 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Verrica Pharmaceuticals Total Liabilities?

Verrica Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 was €59.62 Mil.

Verrica Pharmaceuticals's quarterly Total Liabilities increased from Sep. 2023 (€51.39 Mil) to Dec. 2023 (€56.70 Mil) and increased from Dec. 2023 (€56.70 Mil) to Mar. 2024 (€59.62 Mil).

Verrica Pharmaceuticals's annual Total Liabilities declined from Dec. 2021 (€42.06 Mil) to Dec. 2022 (€4.43 Mil) but then increased from Dec. 2022 (€4.43 Mil) to Dec. 2023 (€56.70 Mil).

Verrica Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Verrica Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verrica Pharmaceuticals Total Liabilities Chart

Verrica Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

3.07

33.84

42.06

4.43

56.70

Verrica Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															3.54	6.28	51.39	56.70	59.62

Verrica Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Verrica Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	15.611	+	(41.091	+	-7.105427357601E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	56.70

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	74.824	-	18.123
	=	56.70

Verrica Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	17.816	+	(41.799	+	7.105427357601E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	59.62

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	61.002	-	1.387
	=	59.62

Verrica Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Verrica Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Verrica Pharmaceuticals (FRA:1NE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verrica Pharmaceuticals Inc (FRA:1NE) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

VRCA:USA 1NE:Germany

Address

44 West Gay Street, Suite 400, West Chester, PA, USA, 19380

Website

https://www.verrica.com

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its lead product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a highly contagious and primarily pediatric viral skin disease, and common warts.

Verrica Pharmaceuticals (FRA:1NE) Headlines

No Headlines